Agios Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 118.08, 258.33, 392.36, 531, 693.83 ], "ebit_estimate": [ -421.51, -346.56, -244.93, -191.3, -38.73 ], "ebitda_estimate": [ -433.63, -348.92, -252.78, null, null ], "net_income_estimate": [ -372.93, -291.69, -212.75, -153.51, -4.33 ], "per_share_eps_estimate": [ -6.25, -4.69, -3.62, -2.47, -0.17 ], "eps_nri_estimate": [ -6.29, -4.75, -3.45, -2.47, -0.17 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 14.16, 10.15, 7.13, null, null ], "pretax_income_estimate": [ -373.01, -299.83, -206.03, -153.29, -1.95 ], "operating_cash_flow_per_share_estimate": [ -5.66, -4.87, -3.19, null, null ], "roa_estimate": [ -37.9, -36, -39.3, null, null ], "roe_estimate": [ -37.23, -37.56, -31.98, null, null ], "gross_margin_estimate": [ 89.9, 90, 88, 88, 88 ], "operating_cash_flow_estimate": [ -332.41, -286.27, -187.52, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 21.75, "long_term_revenue_growth_rate_mean": "96.03", "future_per_share_eps_estimate_growth": 20.69, "future_eps_nri_estimate_growth": 21.75, "future_revenue_estimate_growth": 96.03, "future_ebit_estimate_growth": 19.46, "future_ebitda_estimate_growth": 18.6, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 20.02, "future_pretax_income_estimate_growth": 20.63, "future_book_value_per_share_estimate_growth": -29.45, "future_roa_estimate_growth": -10.27, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 20.16 }

{ "date": [ "202606", "202609", "202612", "202703" ], "revenue_estimate": [ 25.88, 32.46, 38.99, 36.2 ], "ebit_estimate": [ -111.31, -102.02, -98.02, -102.6 ], "ebitda_estimate": [ -112.91, -107.22, -106.24, -101.7 ], "net_income_estimate": [ -99.38, -89.37, -82.98, -87.23 ], "per_share_eps_estimate": [ -1.68, -1.5, -1.39, null ], "eps_nri_estimate": [ -1.68, -1.51, -1.41, -1.5 ], "dividend_estimate": [ null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null ], "pretax_income_estimate": [ -99.84, -89.26, -82.93, -87.23 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null ], "roa_estimate": [ null, null, null, null ], "roe_estimate": [ -36.34, -35.78, -32.57, -38.41 ], "gross_margin_estimate": [ 88, 88, 88, null ], "operating_cash_flow_estimate": [ null, null, null, null ], "pettm_estimate": [ null, null, null, null ], "long_term_growth_rate_mean": 21.75, "long_term_revenue_growth_rate_mean": "96.03", "future_per_share_eps_estimate_growth": 20.69, "future_eps_nri_estimate_growth": 21.75, "future_revenue_estimate_growth": 96.03, "future_ebit_estimate_growth": 19.46, "future_ebitda_estimate_growth": 18.6, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 20.02, "future_pretax_income_estimate_growth": 20.63, "future_book_value_per_share_estimate_growth": -29.45, "future_roa_estimate_growth": -10.27, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 20.16 }